OC
VKTX icon

Oppenheimer & Co’s Viking Therapeutics VKTX Stock Holding History

Oppenheimer & Co’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.71M Sell
146,259
-3,874
-3% -$125K 0.06% 317
2026
Q1 		$4.89M Sell
150,133
-6,520
-4% -$210K 0.06% 341
2025
Q4 		$5.51M Sell
156,653
-27,661
-15% -$980K 0.08% 285
2025
Q3 		$4.84M Buy
184,314
+26,086
+16% +$778K 0.06% 351
2025
Q2 		$4.19M Buy
158,228
+13,685
+9% +$360K 0.06% 364
2025
Q1 		$3.49M Buy
144,543
+23,481
+19% +$742K 0.05% 385
2024
Q4 		$4.87M Buy
121,062
+18,738
+18% +$1.07M 0.07% 295
2024
Q3 		$6.48M Buy
102,324
+31,011
+43% +$1.82M 0.1% 225
2024
Q2 		$3.78M Buy
71,313
+22,369
+46% +$1.47M 0.06% 336
2024
Q1 		$4.01M Buy
48,944
+18,087
+59% +$805K 0.07% 322
2023
Q4 		$574K Buy
30,857
+14,038
+83% +$184K 0.01% 930
2023
Q3 		$186K Buy
16,819
+4,068
+32% +$58.2K ﹤0.01% 1272
2023
Q2 		$207K Buy
+12,751
New +$267K ﹤0.01% 1278

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Oppenheimer & Co's VKTX Position: Q2 2026 in Review

Oppenheimer & Co reduced its Viking Therapeutics (VKTX) stake by 2.6% in Q2 2026, selling an estimated $125K and leaving 146,259 shares worth $5.71M. The position accounts for 0.06% of the portfolio, ranked #317.

Oppenheimer & Co first reported a position in VKTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $6.48M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Oppenheimer & Co held 146,259 shares of Viking Therapeutics worth $5.71M as of Q2 2026.
  • Oppenheimer & Co sold 3,874 Viking Therapeutics shares in Q2 2026, an estimated $125K.
  • Viking Therapeutics made up 0.06% of Oppenheimer & Co's portfolio in Q2 2026, its #317 holding.
  • Oppenheimer & Co first reported a position in Viking Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Oppenheimer & Co's Viking Therapeutics position peaked at $6.48M in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.